

GenBody Inc.
CHANGE AND INNOVATION

COVID-19 Quick Immunoassay

GenBody
COVID-19 IgM/IgG test
Rapid immunoassay for COVID-19 infection

Test Methods During Infection Period Of COVID-19



The outbreak of the novel coronavirus (COVID-19) rapidly transmit all over China and lots of countries. Although molecular test (RT-PCR) has become the standard method for diagnosis of this disease, the method has many limitations. In addition, the high false negative rates were reported. There is an urgent need for an accurate and rapid testing method that quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients.

GenBody COVID-19 IgM/IgG device is a chromatographic immunoassay kit for the rapid and differential detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) against COVID-19 using serum, plasma and whole blood.

Comparison With Molecular Testing

	Molecular Testing (RT-PCR)	GenBody COVID-19 IgG/IgM Rapid Test
Principle	Nucleic acid test of COVID-19	Antibody (IgM & IgG) detection in the bloods
Accuracy in the fields	-China: 30 ~ 50% (Jungangilbo.2020.02.13) -Depending on the swab positioning of specimen and yield of gene extraction	-Before Day 5: very low -After Day 5: 50 ~ 81% for IgM, 81 ~ 100% for IgG
Test time	>6 hours	10 minutes
Test cost	Very expensive	Economic
Users	Skilled & trained	Normal
Specimen	Throat, anal, nasopharyngeal, sputum	Whole blood, serum, plasma
Test capacity	Limited	Possible to bulk testing
Adv/disadvantages	• Good accurate at early stage. • Difficult to detect at latent or asymptomatic period. • Appropriate for early stage with limited cases of patients	• Possible to detect at latent or asymptomatic period. • Inaccurate at from Day 0 to Day 5 after infection • Appropriate for 5 day-after with bulk cases of patients

Diagnostic Accuracy of GenBody COVID-19 IgM/IgG

Parameters	Performance (Ongoing)	Comments
Analytical sensitivity	1.84 S/CO for IgM 1.57 S/CO for IgG	w. ELISA
Sensitivity	Day 3 after symptom: IgM- 30%, IgG- 0% After Day 7 from symptom: IgM- 80%, IgG- >95%	w. limited cases
Specificity	IgM 98% (118/120), IgG: 99% (119/120)	

Interpretation Method

Molecular test	Antibody test		Interpretation
	IgM	IgG	
Positive	Negative	Negative	Acute infection (D1 ~ D3)
Positive	Positive	Negative	Acute infection (D3 ~ D8)
Positive	Positive	Positive	Infected (D8 ~ D15)
Positive	Negative	Positive	Infected (>D15) or secondary infected
Negative	Positive	Negative	Early stage of infection. Need the additional molecular test
Negative	Positive	Positive	Infection (D8 ~ D15), Need the additional molecular test
Negative	Negative	Positive	Past infection or (If IgG negative change to IgG positive) infected
Negative	Negative	Negative	Not infected

Ordering Information

Cat no.	Product Name	Package	Box Size (mm)	Carton Size(mm)
COVI025	GenBody COVID-19 IgM/IgG	10 Tests/Kit	160x100x75	470x420x470

GenBody Inc.
CHANGE AND INNOVATION
GenBody Building, 3-18, Eopseong 2-gil, Seobuk-gu, Cheonan-si, Chungnam, 31077, Korea
Tel : +82-41-523-8990, Fax : +82-41-523-8991, Website : www.genbody.co.kr

GenBody Inc.
(주)젠바디

Confidential

Clinical Study Report

Of

GenBody COVID-19 IgM/IgG RDT

Product: **GenBody COVID-19 IgM/IgG**

Date: **2020-03-12**

GenBody Inc.
(주)젠바디

Confidential

Clinical evaluation of GenBody COVID-19 IgM/IgG Rapid Diagnostic Test

1. Introduction

The outbreak of the novel coronavirus (COVID-19) rapidly transmit all over China and lots of countries. Although molecular test (RT-PCR) has become the standard method for diagnosis of this disease, the method have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid testing method that quickly identify large number of infected patients andasymptomatic carriers to prevent virus transmission and assure timely treatment of patients. GenBody COVID-19 IgM/IgG device is a chromatographic immunoassay kit for the rapid and differential detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) against COVID-19 using serum, plasma and whole blood.

The recombinant COVID-19 antigen was coated on the membrane and anti-human IgM and IgG monoclonal antibody was conjugated the gold particles, respectively. When the specimen existing anti-COVID-19 antibodies is loaded into a sample well (S), the antibodies are complexed with anti-human IgM (or IgG) gold conjugate. And this complex migrates and captured by the immobilized recombinant COVID-19 antigens to make a visible band in the test line regions, M and G. The solution continues to migrate to the control line (C) region that binds a control conjugate, thereby producing another red line. GenBody COVID-19 IgM/IgG can detect the antibodies against COVID-19, so that the device is suitable for the diagnosis of COVID-19 infections.

2. Study purpose

To evaluate the clinical performance of GenBody COVID-19 IgM/IgG Rapid Test

3. Study design

1) One lot of device
2) Origin of clinical samples: Dankook University Hospital (Korea) and Dongbang Hospital Shanghai (China)
3) One time per sample
4) Instrument: N/A
5) One operator
6) Sample type: serum, plasma, whole blood
7) Study site: Dankook University Hospital (Korea) and Dongbang Hospital

Shanghai (China)

4. Methods of statistical analysis

4.1 Instrument

N/A

4.2 Reagent & Material

① Test device: GenBody COVID-19 IgM/IgG Rapid Diagnostic Test

② Reference method: RT-PCR (Seegene Inc., Korea)

4.3 Sample preparation

A study was performed by skilled clinicians using total 159 sera (39 positives and 120 negatives) that were collected by Dankook University Hospital (under IRB approval for research purpose) and Dongbang Hospital Shanghai.

4.4 Test procedure

1) All specimens and test devices should be prepared with warm condition, that is, for 15~30 min at room temperature before testing.
2) All testing were followed by the kit manual.

5. Results

5.1 For IgM

For IgM N= 159		RT-PCR			
		Before Day 3 from symptom		After Day 7 from symptom	
		Positive	Negative	Positive	Negative
GenBody COVID-19 IgM/IgG	Positive	3	1	25	1
	Negative	6	119	5	119
Total		9	120	30	120
Sensitivity (Before Day 3/After Day 7)= 30% (3/9) / 80% (25/30) Specificity= 99%					

5.2 For IgG

For IgG	RT-PCR

N= 159		Before Day 3 from symptom		After Day 7 from symptom	
		Positive	Negative	Positive	Negative
GenBody COVID-19 IgM/IgG	Positive	0	0	30	0
	Negative	9	120	0	120
Total		9	120	30	120
Sensitivity (Before Day 3/After Day 7)= 0% (0/9) / 100% (30/30) Specificity= 100%					

5.3 Summary of results

GenBody COVID-19 IgM/IgG Rapid test showed the excellent sensitivity and specificity after Day 7 from symptom. Its overal diagnostic performance was the below. However, before Day 3 after symptom, its diagnostic accuracy was low because there was not enough time to generate the antibodies after infections (30% of sensitivity and 99.5% of specificity).\

1) Before Day 3 from sypmptom
- **Sensitivity= 30% for IgM, 0% for IgG**
- **Specificity= 99% for IgM, 100% for IgG**

2) Before Day 7 from sypmptom
- **Sensitivity= 80% for IgM, 100% for IgG**
- **Specificity= 99% for IgM, 100% for IgG**

6. Conclusion

The overal sensitivity and specificity of GenBody COVID-19 IgM/IgG was 100% and 99.5%, respectively, comparing with molecular testing (RT-PCR), which are combinated calculation of IgM and IgG.

GenBody Inc.
(주)젠바디

Confidential

[Dataset] Clinical study raw data (Positive: 39, Negative: 120)

(+, Positive; N, Negative)

No	Specimen	Sample collection time	RT-PCR	GenBody COVID-19 IgM/IgG	
				IgM	IgG
1	DK011020	Before Day 3 from symptom	+	N	N
2	DK021020	Before Day 3 from symptom	+	N	N
3	DK111020	Before Day 3 from symptom	+	N	N
4	DK011023	Before Day 3 from symptom	+	P	N
5	DK011024	Before Day 3 from symptom	+	P	N
6	DK021021	Before Day 3 from symptom	+	N	N
7	DK021022	Before Day 3 from symptom	+	N	N
8	DB021020	Before Day 3 from symptom	+	P	N
9	DB021024	Before Day 3 from symptom	+	N	N
10	DK121020	After Day 7 from symptom	+	+	+
11	DK121120	After Day 7 from symptom	+	+	+
12	DK121121	After Day 7 from symptom	+	+	+
13	DK121122	After Day 7 from symptom	+	+	+
14	DK121123	After Day 7 from symptom	+	N	+
15	DK121124	After Day 7 from symptom	+	+	+
16	DK121125	After Day 7 from symptom	+	+	+
17	DK121126	After Day 7 from symptom	+	+	+
18	DK121127	After Day 7 from symptom	+	+	+
19	DK121128	After Day 7 from symptom	+	N	+
20	DK121129	After Day 7 from symptom	+	+	+
21	DK122101	After Day 7 from symptom	+	N	+
22	DK122102	After Day 7 from symptom	+	+	+
23	DK122103	After Day 7 from symptom	+	+	+
24	DK122104	After Day 7 from symptom	+	+	+
25	DK122105	After Day 7 from symptom	+	+	+
26	DK122106	After Day 7 from symptom	+	+	+
27	DK122107	After Day 7 from symptom	+	+	+
28	DB122001	After Day 7 from symptom	+	+	+
29	DB122002	After Day 7 from symptom	+	+	+
30	DB122003	After Day 7 from symptom	+	+	+
31	DB122004	After Day 7 from symptom	+	+	+
32	DB122005	After Day 7 from symptom	+	+	+
33	DB122006	After Day 7 from symptom	+	+	+
34	DB122007	After Day 7 from symptom	+	N	+
35	DB122008	After Day 7 from symptom	+	N	+
36	DB122009	After Day 7 from symptom	+	+	+
37	DB122010	After Day 7 from symptom	+	+	+
38	DB122011	After Day 7 from symptom	+	+	+
39	DB122012	After Day 7 from symptom	+	+	+
40	DK100201	No History	N	N	N
41	DK100202	No History	N	N	N
42	DK100203	No History	N	N	N
43	DK100204	No History	N	N	N

44	DK100205	No History	N	N	N
45	DK100206	No History	N	N	N
46	DK100207	No History	N	N	N
47	DK100208	No History	N	N	N
48	DK100209	No History	N	N	N
49	DK100210	No History	N	N	N
50	DK100211	No History	N	N	N
51	DK100212	No History	N	N	N
52	DK100213	No History	N	N	N
53	DK100214	No History	N	N	N
54	DK100215	No History	N	N	N
55	DK100216	No History	N	N	N
56	DK100217	No History	N	N	N
57	DK100218	No History	N	N	N
58	DK100219	No History	N	N	N
59	DK100220	No History	N	N	N
60	DK100221	No History	N	N	N
61	DK100222	No History	N	N	N
62	DK100223	No History	N	+	N
63	DK100224	No History	N	N	N
64	DK100225	No History	N	N	N
65	DK100226	No History	N	N	N
66	DK100227	No History	N	N	N
67	DK100228	No History	N	N	N
68	DK100229	No History	N	N	N
69	DK100230	No History	N	N	N
70	DK100231	No History	N	N	N
71	DK100232	No History	N	N	N
72	DK100233	No History	N	N	N
73	DK100234	No History	N	N	N
74	DK100235	No History	N	N	N
75	DK100236	No History	N	N	N
76	DK100237	No History	N	N	N
77	DK100238	No History	N	N	N
78	DK100239	No History	N	N	N
79	DK100240	No History	N	N	N
80	DK100241	No History	N	N	N
81	DK100242	No History	N	N	N
82	DK100243	No History	N	N	N
83	DK100244	No History	N	N	N
84	DK100245	No History	N	N	N
85	DK100246	No History	N	N	N
86	DK100247	No History	N	N	N
87	DK100248	No History	N	N	N
88	DK100249	No History	N	N	N
89	DK100250	No History	N	N	N
90	DK100251	No History	N	N	N
91	DK100252	No History	N	N	N
92	DK100253	No History	N	N	N
93	DK100254	No History	N	N	N

94	DK100255	No History	N	N	N
95	DK100256	No History	N	N	N
96	DK100257	No History	N	N	N
97	DK100258	No History	N	N	N
98	DK100259	No History	N	N	N
99	DK100260	No History	N	N	N
100	DK100261	No History	N	N	N
101	DK100262	No History	N	N	N
102	DK100263	No History	N	N	N
103	DK100264	No History	N	N	N
104	DK100265	No History	N	N	N
105	DK100266	No History	N	N	N
106	DK100267	No History	N	N	N
107	DK100268	No History	N	N	N
108	DK100269	No History	N	N	N
109	DK100270	No History	N	N	N
110	DK100271	No History	N	N	N
111	DK100272	No History	N	N	N
112	DK100273	No History	N	N	N
113	DK100274	No History	N	N	N
114	DK100275	No History	N	N	N
115	DK100276	No History	N	N	N
116	DK100277	No History	N	N	N
117	DK100278	No History	N	N	N
118	DK100279	No History	N	N	N
119	DK100280	No History	N	N	N
120	DK100281	No History	N	N	N
121	DK100282	No History	N	N	N
122	DK100283	No History	N	N	N
123	DK100284	No History	N	N	N
124	DK100285	No History	N	N	N
125	DK100286	No History	N	N	N
126	DK100287	No History	N	N	N
127	DK100288	No History	N	N	N
128	DK100289	No History	N	N	N
129	DK100290	No History	N	N	N
130	DK100291	No History	N	N	N
131	DK100292	No History	N	N	N
132	DK100293	No History	N	N	N
133	DK100294	No History	N	N	N
134	DK100295	No History	N	N	N
135	DK100296	No History	N	N	N
136	DK100297	No History	N	N	N
137	DK100298	No History	N	N	N
138	DK100299	No History	N	N	N
139	DK100300	No History	N	N	N
140	DK100301	No History	N	N	N
141	DK100302	No History	N	N	N
142	DK100303	No History	N	N	N
143	DK100304	No History	N	N	N

144	DK100305	No History	N	N	N
145	DK100306	No History	N	N	N
146	DK100307	No History	N	N	N
147	DK100308	No History	N	N	N
148	DK100309	No History	N	N	N
149	DK100310	No History	N	N	N
150	DK100311	No History	N	N	N
151	DK100312	No History	N	N	N
152	DK100313	No History	N	N	N
153	DK100314	No History	N	N	N
154	DK100315	No History	N	N	N
155	DK100316	No History	N	N	N
156	DK100317	No History	N	N	N
157	DK100318	No History	N	N	N
158	DK100319	No History	N	N	N
159	DK100320	No History	N	N	N

-END.

GENBODY COVID-19 IGM/IGG IS NOW AVAILABLE

WHO declared, as of 12th March 2020, the outbreak of COVID-19 is a pandemic



COVID-19 has started in Wuhan, China, where is known as epicenter of this disease now prevailing around the globe. As of March 2020, the number of infected citizens (in total of 118,381 individuals are affected as of 12th March 2020) is soaring rapidly around the globe.



COVID-19 Status

4,292 deaths
114 countries, areas or territories with cases

PCR test is currently used in most affected countries as confirmatory test, and Rapid Test is not considered or performed as confirmatory test. However, with the advantage of short testing time of Rapid Test, no requirement of equipment and skilled technicians, rapid test can role as a first screening and/or complimentary option of PCR Test.

Please refer to the table below for Sensitivity and Specificity Information

Diagnostic Accuracy of GenBody COVID-19 IgM/IgG		
Parameters	**Performance (Ongoing)**	**Remark**
Analytical Sensitivity	1.84 s/CO for IgM 1.57 s/CO for IgG	w. In-house ELISA
Sensitivity	3 cases at Day 3: IgM - 30%, IgG - 0% 5 cases at Day 8: IgM - 40%, IgG - 100%	w. limited cases
Specificity	IgM: 98% (118/120), IgG: 90% (119/120)	

In case you have urgent need for this product in your country, we hope we can contribute to you to fight against this outbreak.

Please note that as this product was developed to meet the emergent need of the outbreak, the regulatory process by national & international regulatory authorities are still under process.

Please contact your Regional Manager for more information.

GenBody Inc.

CORPORATE PRESENTATION

GenBody Inc.
CHANGE AND INNOVATION

Contents

GenBody Inc.
CHANGE AND INNOVATION



Press Releases

GenBody Inc.
CHANGE AND INNOVATION

Zika / Dengue / Chikungunya / Yellow Fever Virus Diagnostic Test Kits by PCR, ELISA, RDTs technology

TESTES RÁPIDOS DE ZIKA MADE IN BAHIA

Governador anunciou que a Bahiafarma, em parceria com empresa sul-coreana, produzirá o exame para diagnosticar o vírus em poucos minutos

Praticidade
Resultado em 20 minutos

"É uma informação positiva a possibilidade de termos isso na rede pública e de em 20 minutos sair o resultado, já que temos dificuldade com sorologias", disse Manoel Sarno, pesquisador e professor de obstetrícia da Faculdade de Medicina da Universidade Federal da Bahia (Ufba). A Bahia notificou, segundo a Sesab, 1.074 casos de microcefalia até o último dia 19.

O primeiro do Brasil
Caso ocorra o anúncio oficial na segunda-feira, trata-se de um feito histórico para a indústria farmacêutica baiana. O teste rápido para a doença é inédito no País e, de acordo com a Secretaria da Saúde do Estado da Bahia (Sesab), também é o primeiro teste diagnóstico feito sem a participação da Fundação Oswaldo Cruz (Fiocruz). O teste torna mais fácil e rápida a detecção do vírus em pessoas infectadas.

Governo confirma que laboratório baiano fará 1º teste rápido da zika

Bahiafarma prepara-se para fazer teste rápido de detecção do zika

Ministério da Saúde investiga casos da doença

Mission & Core Value

GenBody Inc.
CHANGE AND INNOVATION

Innovation for New Technology

Responsibility to Society

Think Human First

Milestones

GenBody Inc.
CHANGE AND INNOVATION



Facility

GenBody Inc.
CHANGE AND INNOVATION

Head office

Production Line

R&D Center

Administration

Innovation Center

Production & Storage

R&D Center

Seminar room

Suji R&D center

Financial Dept.

R&D Center

Production

GenBody Inc.
CHANGE AND INNOVATION

Automated system for mass production


ISO13485


ISO9001


GMP

Global Network

GenBody Inc.
CHANGE AND INNOVATION

GenBody Global Network



Domestic Network

GenBody Inc.
CHANGE AND INNOVATION



국립보건원 Korea National Institute of Health	단국대학교 Korea National Institute of Health	㈜옵토레인 Optolane Inc	가톨릭대학교 The Catholic University of Korea	원광대학교 Wonkwang University	카이스트 KAIST
충북대학교 Chungbuk National University	한국생명공학연구원 KRIBB	건국대학교 Konkuk University	고려대학병원 Korea University Medical Center	중앙대학교 Chung-ang University	인하대학교 Inha University

Turnover

GenBody Inc.
CHANGE AND INNOVATION



Patents

GenBody Inc.
CHANGE AND INNOVATION

Domestic

Application No	Title
10-2008-0047070	Fullerene-silica nanoparticles having improved luminescence, preparation method thereof and use thereof
10-2011-0038199	Water Soluble Fluorescent Fullerene Derivatives and Method for Preparing the Same
10-2011-0032688	Portable fluorescence detection system
10-2012-0075904	Condensing type portable fluorescence detection system
10-2010-0016738	Novel coumarin derivatives, process for the preparation thereof, and kits comprising the coumarin derivatives for fluorescent immunosorbant assay
10-2012-0022564	Novel coumarindendrimer fluorophore and a highly sensitive LED-based real-time biomonitoring system using thereof
10-2014-0002947	Rapid diagnostic kit for detecting anti-dengue virus antibodies using monoclonal antibody specific to the domain 1 of dengue envelope protein and its manufacturing method
10-2016-012673	Kit for fluorescence-linked immunochromatographic assay to diagnose brucellosis
10-2016-0153950	A Method of Detecting Anti-Zika Virus Antibodies Using Monoclonal Antibody Specific to the Zika Envelope and Non-Structural Protein 1 and Rapid Diagnostic Kit for Detecting Anti-Zika Virus Antibodies
10-2017-0050993	Immunochromatographic strip comprising fullerene-europium complex and its use
10-2017-0067735	Specific antigen purification method and monoclonal antibody production method using the same

Patents

GenBody Inc.
CHANGE AND INNOVATION

Overseas

Application No	Title
11 775 226.1	Water Soluble Fluorescent Fullerene Derivatives and Method for Preparing the Same
13/643,292	Water Soluble Fluorescent Fullerene Derivatives and Method for Preparing the Same
2013-507874	Water Soluble Fluorescent Fullerene Derivatives and Method for Preparing the Same
14/350,035	Novel coumarindendrimer fluorophore and a highly sensitive LED-based real-time biomonitoring system using thereof
201280049495.6	Novel coumarindendrimer fluorophore and a highly sensitive LED-based real-time biomonitoring system using thereof

PCT

Priority application number/date	Applicant	Inventors	Title
10-2016-0153950 (2016. 11. 18.)	GenBody Inc. / BioNano Health Guard Research Center	Chom Kyu Chong, Yongbeom Shin, Pan Gi Bae, Yeong Eun Kim, Ji Hoo Lee, So Yeon Lee, Jeong Seon Kwon, Ui Jin Lee, Seung Sik Shin	A Method of Detecting Anti-Zika Virus Antibodies Using Monoclonal Antibody Specific to the Zika Envelope and Non-Structural Protein 1 and Rapid Diagnostic Kit for Detecting Anti-Zika Virus Antibodies

Product Range - RDTs (for Human)

GenBody Inc.
CHANGE AND INNOVATION

GenBody ArboTest Series

15 min	2°C-30°C 35.6°F-86°F	24 months	
FAST RESULTS	STORAGE TEMPERATURE	SHELF LIFE	SPECIMEN : serum,plasma, whole blood

MERS-CoV	Zika	Lassa fever	Yellow fever	ArboTest – DZCMY	Mayaro fever	O fever
MERS-CoV Ag	Zika NS1 Ag Zika IgG/IgM	Lassa IgG/IgM	YFV NS1 Ag YFV IgG/IgM DV/YFV NS1 Ag	Mayaro IgM	Dengue, Zika, Chikungunya, Mayaro, Yellow fever	Oropouche Ag Oropouche IgG/IgM

Product Range - RDTs (for Human)

GenBody Inc.
CHANGE AND INNOVATION

Arboviral Disease

- Dengue IgG/IgM
- Dengue NS1 Antigen
- Dengue Ag/Ab Combo
- YFV IgG/IgM
- YFV NS1 Antigen
- Dengue/YFV Ag Combo
- Zika IgG/IgM
- Zika IgM
- Zika IgG
- Zika NS1 Antigen
- Arbo–DZC Ab Combo
- Chikungunya IgM
- Chikungunya IgG/IgM
- Mayaro IgM

Malaria

- Malaria Pf/Pv Ab
- Malaria Pf/Pan Ag
- Malaria Pf/Pv Ag II
- Malaria Pf Ag
- Malaria Pan Ag
- Malaria Pf/Pv Ag

Febrile Disease

- Leptospira IgG/IgM
- Leptospira Ab
- Leishmania Ab
- Tsutsugamushi Ab

Blood–borne Disease

- HIV 1/2 (2 line)
- HIV 1/2 (3 line)
- HCV
- HBsAg
- Anti–HBs
- HAV IgG/IgM

STD (Sexually Transmitted Disease)

- Syphilis
- Chlamydia
- HIV/Syphilis Combo

Respiratory Disease

- Influenza A/B Ag
- RSV Ag
- Strep A Ag
- Mycoplasma Ag
- Mycoplasma IgG/IgM

Cardiac Marker

- cTnI
- CK–MB/Myo/cTnI
- D–dimer

Gastrointestinal Disease

- Adenovirus Ag
- Typhoid IgM/IgG
- Typhoid Ag
- Rotavirus Ag
- H.pylori Ab
- H.pylori Ag
- Norovirus Ag
- Noro/Rota Ag

Cancer Marker

- AFP
- CA15–3
- CA 125
- CEA
- PSA
- FOB

Other Infectious Disease

- Toxoplasma IgM/IgG
- Toxoplasma Ab

DOA (Drug of Abuse)

- DOA6
- Multi–DOA6
- DOA8
- 13 parameters
  (MET/AMP/MOR/THC/PCP/MTD/COC/MDMA/BAR/BZO/TCA/KET/K2)

We have over 75 products totally and planning to launch 10 kinds of new products.

Product Range - RDTs (for Veterinary)

GenBody Inc.
CHANGE AND INNOVATION

Vaccination Check

NEW

CPV Ab

NEW

CDV Ab

NEW

CPV/CDV Ab

NEW

FPV Ab

Leptospira Ab

Veterinary RDTs for 36 parameters with POCT analyzer

Product Range - RDTs (for Veterinary)

GenBody Inc.
CHANGE AND INNOVATION



Gastrointestinal Disease

- CCV Ag
- CPV Ag
- FCoV Ag
- FPV Ag
- Giardia Ag
- Rota Ag
- CCV/CPV Ag

Respiratory Disease

- CDV Ag
- CIV Ag
- CAV2 Ag
- FCV Ag
- FHV Ag
- CDV/CIV Ag
- CDV/CAV2 Ag

Allergy

- Canine IgE

Feline Infectious Disease

- FIV Ab
- FeLV Ag
- FIV Ag/Ab
- FeLV Ag/FIV Ab

Parasitic Disease and Others

- B.canis Ab
- E.canis Ab
- Tg Ab
- Canine Tg IgM/IgG
- Feline Tg IgM/IgG
- Leishmania Ab
- Leptospira Ab
- ICH Ag
- D–Dimer
- CPV Ab
- CDV Ab
- CPV/CDV Ab
- CHW Ag
- cTnI
- FPV Ab

Bovine Brucellosis and Neospora

- B.abortus Ab
- Neospora Ab

New item – coming soon

- Anaplasma Ab
- Lyme Ab
- HEAL Combo (Heartworm/Ehrlichia/Anaplasma/Lyme)

Product Range

GenBody Inc.
CHANGE AND INNOVATION

POCT

Confiscope G20 analyzer

NEW

Fast Result

Easy to Use

800g
Portable

QR code

Wi-Fi

Product Range

GenBody Inc.
CHANGE AND INNOVATION

POCT

Confiscope F10 Analyzer

LAN Printer QR Code

< Human IVD >

Parameters:

- **AMH, Vitamin D, CRP, PCT, pro-BNP**

- PhotoDiode Scan / UV-LED
- Data storage : over 1,000 tests
- External USB Port : Backup, Update, Charging
- Embedded Sub-Battery Pack

Confiscope F20 Analyzer

RFID Wi-Fi Portable

High sensitivity User friendly Quantitative & qualitative

Simple & quick Room temperature storage

< Human IVD >

Parameters:

- **Influenza A/B Ag**
- **Mycoplasma IgG/IgM**
- **Mycoplasma Ag**

- 2M CMOS CAM module / UV-LED
- Data storage : over 1,000 tests
- External USB Port : Backup, Update, Charging

Product Range

Enzyme-Linked Immunosorbent Assay (ELISA)



ELISA				
Cat. No	**Name**	**Specimen**	**Package (/kit)**	**Description**
EDVAG01	Dengue NS1 Antigen ELISA	S	96 tests	Dengue NS1 antigen
EDVIG01	Dengue IgG ELISA	S	96 tests	Dengue IgG
EDVIM01	Dengue IgM ELISA	S	96 tests	Dengue IgM
EZIKG01	Zika IgG ELISA	S	96 tests	Zika IgG
EZIKM01	Zika IgM ELISA	S	96 tests	Zika IgM
ECHIKG1	Chikungunya IgG ELISA	S	96 tests	Chikungunya IgG
ECHIKM1	Chikungunya IgM ELISA	S	96 tests	Chikungunya IgM
EYFAG01	Yellow fever NS1 Antigen ELISA	S	96 tests	Yellow fever NS1 antigen
EYFIG01	Yellow fever IgG ELISA	S	96 tests	Yellow fever IgG
EYFIM01	Yellow fever IgM ELISA	S	96 tests	Yellow fever IgM

Product Range

GenBody Inc.
CHANGE AND INNOVATION

PCR REAL-TIME MULTIPLEX

Dengue
Zika
Chikungunya
Mayaro
Yellow fever

Product Range

GenBody Inc.
CHANGE AND INNOVATION

Diagnostic Reagents

Latex turbidimetric immunoassay

High sensitivity clinical chemistry reagent

CRP RPR TP

Clinical Chemistry Reagents

Over 60 products available

Product Range

GenBody Inc.
CHANGE AND INNOVATION

OEM & ODM

Assembled Products

- Blank pouch
- Assembled kit
- Buffer

Uncut Sheet Material

- Optimized cassettes
- Laminated uncut sheet (or) separate components
- Technical Support for local production set up

Reagent Supply

- Recombinant Antigen
- Monoclonal Antibody

International Exhibition

GenBody Inc.
CHANGE AND INNOVATION

MEDICA Germany

MEDLAB Dubai UAE

AACC USA

W.V.C. USA

London Vet Show, UK

To be No.1 Global Diagnostic Group

GenBody Inc.
CHANGE AND INNOVATION